Rochefort H
INSERM U. 148, Université de Montpellier I, France.
Horm Res. 1987;28(2-4):196-201. doi: 10.1159/000180944.
The mechanism of the antiproliferative effect of nonsteroidal antiestrogens (tamoxifen, hydroxytamoxifen) is discussed from studies performed in human breast cancer cell lines. At least two types of mechanism have been evidenced. In the presence of estrogens, antiestrogens behave as classical antihormones and their inhibition of cell proliferation is likely due to inhibition of the synthesis and release of several estrogen-induced mitogens (growth factors and proteases). In the absence of estrogens (cells cultured in phenol-red-free medium), antiestrogens can still inhibit the effect of growth factors (EGF, insulin). At concentrations less than or equal to 4 microM, antiestrogens are also cytotoxic and they require accessible estrogen receptors for their action. 'Estrogen-receptor-targeted drugs' is therefore a better general term than 'antiestrogens' to describe the mechanism of action of these drugs, which can also function without inhibiting estrogen action.
从在人乳腺癌细胞系中进行的研究探讨了非甾体类抗雌激素药物(他莫昔芬、羟基他莫昔芬)抗增殖作用的机制。已证实至少有两种机制。在雌激素存在的情况下,抗雌激素表现为经典的抗激素,其对细胞增殖的抑制可能是由于抑制了几种雌激素诱导的有丝分裂原(生长因子和蛋白酶)的合成与释放。在无雌激素的情况下(在无酚红培养基中培养的细胞),抗雌激素仍可抑制生长因子(表皮生长因子、胰岛素)的作用。在浓度小于或等于4微摩尔时,抗雌激素也具有细胞毒性,且其作用需要可及的雌激素受体。因此,“雌激素受体靶向药物”比“抗雌激素”是一个更好的通用术语来描述这些药物的作用机制,这些药物也可在不抑制雌激素作用的情况下发挥功能。